Taurohyocholic Acid
(Synonyms: 牛磺胆酸,Tauro-γ-muricholic Acid) 目录号 : GC45574Taurohyocholic Acid是一种由猪胆酸衍生的结合牛磺酸的胆汁酸，主要存在于猪胆汁中。
Cas No.:32747-07-2
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Taurohyocholic Acid is a taurine-conjugated bile acid derived from hyocholic acid, predominantly found in pig bile[1]. Taurohyocholic Acid plays a crucial role in glucose homeostasis[2] and metabolic regulation[3]. It is also used in research of oncology[4] and end-stage renal disease (ESRD)[5] as a biomarker for predicting treatment efficacy.
Taurohyocholic Acid stimulate GLP-1 production and secretion in intestinal enteroendocrine STC-1 and NCI-H716 cells by promoting proglucagon transcription. In STC-1 and NCI-H716 cells, treatment with 25µM Taurohyocholic Acid for 1 hour significantly increased GLP-1 secretion, and a 24-hour incubation further promoted proglucagon transcription and GLP-1 production[6].
References:
[1]. Fang W, Wen X, Meng Q, et al. Alteration in bile acids profile in Large White pigs during chronic heat exposure. J Therm Biol. 2019 Aug;84:375-383. doi: 10.1016/j.jtherbio.2019.07.027. Epub 2019 Jul 26. PMID: 31466777.
[2]. Cheng Z, Liu G, Zhang X, et al. Improvement of Glucose Metabolism Following Long-Term Taurocholic Acid Gavage in a Diabetic Rat Model. Med Sci Monit. 2018 Oct 9;24:7206-7212. doi: 10.12659/MSM.912429. PMID: 30298865; PMCID: PMC6192455.
[3]. Zheng X, Chen T, Zhao A, et al. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat Commun. 2021 Mar 5;12(1):1487. doi: 10.1038/s41467-021-21744-w. PMID: 33674561; PMCID: PMC7935989.
[4]. Chen Y, Wang Y, Lei J, et al. Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma. Front Pharmacol. 2024 Feb 23;15:1364924. doi: 10.3389/fphar.2024.1364924. PMID: 38464731; PMCID: PMC10920247.
[5]. Chen WY, Zhang JH, Chen LL, et al. Bioactive metabolites: a clue to the link between MASLD and CKD? Clin Mol Hepatol. 2024 Oct 21. doi: 10.3350/cmh.2024.0782. Epub ahead of print. PMID: 39428978.
[6]. Zheng X, Chen T, Jiang R, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021 Apr 6;33(4):791-803.e7. doi: 10.1016/j.cmet.2020.11.017. Epub 2020 Dec 17. PMID: 33338411.
Taurohyocholic Acid是一种由猪胆酸衍生的结合牛磺酸的胆汁酸，主要存在于猪胆汁中[1]。Taurohyocholic Acid在维持血糖稳态[2]和代谢调节[3]中起关键作用。在肿瘤学[4]和终末期肾病（ESRD）[5] 研究中，Taurohyocholic Acid可以作为预测治疗效果的生物标志物。
Taurohyocholic Acid可以通过促进前胰高血糖素转录，刺激STC-1和NCI-H716细胞中GLP-1的生成和分泌。在STC-1和NCI-H716细胞中，用25µM的Taurohyocholic Acid处理1小时可以显著增加GLP-1分泌，24小时的孵育进一步促进了前胰高血糖素转录和GLP-1的生成[6]。
| Cell experiment [1]: | |
Cell lines | STC-1 |
Preparation Method | The STC-1 cell were plated into 24 well-plates with an initial cell density of 2*105 cells/well, treated with 25µM Taurohyocholic Acid for 1h. The cell media was removed from the cells, centrifuged at 2,000g for 10min to remove cell debris and the supernatant was collected. An GLP-1 ELISA kit was used to measure GLP-1. |
Reaction Conditions | 25µM, 1h |
Applications | Taurohyocholic Acid can upregulated GLP-1 secretion in STC-1 cells. |
References: | |
| Cas No. | 32747-07-2 | SDF | |
| 别名 | 牛磺胆酸,Tauro-γ-muricholic Acid | ||
| 化学名 | 2-[[(3α,5β,6α,7α)-3,6,7-trihydroxy-24-oxocholan-24-yl]amino]-ethanesulfonic acid | ||
| Canonical SMILES | O[C@@H]1CC[C@@]2(C)[C@@]([C@@H](O)[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCCS(O)(=O)=O)=O)([H])C1 | ||
| 分子式 | C26H45NO7S | 分子量 | 515.7 |
| 溶解度 | 20mg/mL in ethanol, or DMSO, 30mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9391 mL | 9.6956 mL | 19.3911 mL |
| 5 mM | 0.3878 mL | 1.9391 mL | 3.8782 mL |
| 10 mM | 0.1939 mL | 0.9696 mL | 1.9391 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet